2024-03-28T18:06:34Z
https://tsukuba.repo.nii.ac.jp/oai
oai:tsukuba.repo.nii.ac.jp:02001709
2022-04-27T10:00:43Z
2780:1633064495591
3:62:5595:7807
Quality of life and pain in patients with thalidomide embryopathy in Japan
今井, 公文
イマイ, コウブン
IMAI, Kobun
Sone, Hanae
Otomo, Ken
Nakano, Yuki
Hinoshita, Fumihiko
Background
The aim of this study was to assess psychological/psychiatric problems and quality of life (QOL) in patients with thalidomide embryopathy (TE), with a specific focus on pain, including pain severity and the effects of coping strategies for pain.
Methods
A questionnaire survey was conducted to evaluate the severity of pain experienced by patients with TE, pain management strategies, time perspective, mental health status, and QOL. Of 67 patients with TE who underwent a health checkup, 51 respondents who gave valid responses were included in analysis.
Results
GHQ-28 suggested that 41.2% of respondents appeared to potentially have psychiatric disorders. The mean scores of QOL were still within a normal range. There is no significant differences were found between limb disability group and hearing impairment group in QOL or mental health status. About 82.4% of respondents reported that they experience physical pain, and the use of the cognitive coping strategy “catastrophizing” to cope with pain was significantly associated with mental health status and QOL.
Conclusion
This study demonstrate that although some patients with TE have some form of mental health problem, they still maintain a normal range QOL despite their disabilities. In addition, pain was not as strongly associated with mental health problems and QOL as would be expected, and variables such as “catastrophizing” to cope with pain appear to potentially be associated with reduced mental health and QOL.
journal article
Wiley
2020-11
application/pdf
Molecular Genetics & Genomic Medicine
11
8
e1464
2324-9269
https://tsukuba.repo.nii.ac.jp/record/2001709/files/MGGM_8-11.pdf
eng
32893502
https://doi.org/10.1002/mgg3.1464
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC
open access